Appendix B
Polling Results
At two points during the conference, participants attending the workshop in person were given individual keypads to respond to a series of questions posed by John Wagner, chair of the workshop planning committee. He noted that he was sampling a very small population (22 responses were obtained) biased toward seeing the value to collaborations, so the results featured below, though of interest, are by no means scientific or representative of the community of biomedical researchers.
Questions |
Responses |
|
Percentage |
Count |
|
What organization do you represent? |
||
Government |
0 |
0 |
Industry |
32 |
7 |
Academia |
18 |
4 |
Nonprofit |
23 |
5 |
Other |
27 |
6 |
Have you personally participated in a precompetitive collaboration? |
||
Yes |
52 |
11 |
No |
48 |
10 |
Has your institution/company participated in a precompetitive collaboration? |
||
Yes |
77 |
17 |
No |
23 |
5 |
Questions |
Responses |
|
Percentage |
Count |
|
How important do you feel precompetitive collaboration is to biomedical research? |
||
Not at all important |
5 |
1 |
Somewhat important |
0 |
0 |
Important |
5 |
1 |
Very important |
23 |
5 |
Critical |
68 |
15 |
Which research activity do you feel can benefit most from precompetitive collaboration? |
||
Bioinformatics/software development |
4 |
1 |
Data generation/collection efforts |
35 |
8 |
Basic research |
17 |
4 |
Translational/disease-focused research |
35 |
8 |
Product-oriented research |
9 |
2 |
What do you see as the biggest hurdle to precompetitive collaboration in biomedicine? |
||
Individualist/competitive culture among academics |
30 |
6 |
Proprietary culture of industry |
25 |
5 |
Intellectual property issues |
25 |
5 |
Academic promotion/tenure process |
15 |
3 |
Publications |
0 |
0 |
Patient privacy concerns |
5 |
1 |
How relevant/applicable are industry collaborations, such as SEMATECH, to biomedical research? |
||
Not at all important |
0 |
0 |
Somewhat important |
16 |
3 |
Important |
16 |
3 |
Very important |
42 |
8 |
Critical |
26 |
5 |
How relevant/applicable are prizes, such as InnoCentive offers, to biomedical research? |
||
Not at all important |
0 |
0 |
Somewhat important |
42 |
8 |
Important |
26 |
5 |
Very important |
21 |
4 |
Critical |
11 |
2 |